China's first CDK4/6 inhibitor for early breast cancer is officially launched

China Economic and social news, March 6, according to "Lai Lai Lilly" administrative micro blog, in March 6th, Lilai pharmaceutical CDK4 & 6 inhibitor (Alice) was introduced to China in early stage of breast cancer indication. Abe Sealy (CDK4) is the first and only approved inhibitor of the Chinese Drug Administration in the early stage of breast cancer in China. It was approved by the National Drug Administration NMPA in December 2021 and used for combined endocrine therapy (tamoxifen or aromatase inhibitors) for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, and lymph node positive. Adjuvant therapy for adults with early recurrent breast cancer with high recurrence risk and Ki-67 above 20%.